S&K Therapeutics owns an AI (artificial intelligence) based drug development platform that allows to discover new molecular entities effectively. Furthermore, based on extensive research experience on TLRs (Toll-like receptors) and NLRP3 (NACHT, LRR, and PYD domains-containing protein 3), S&K therapeutics is establishing new drug development pipelines for autoimmune diseases, inflammatory diseases, and viral diseases.

  •  🍉  IR Deck (May 2023) - Revolutionizing Biotech: Unveiling Cutting-Edge Technologies and Products

S&K Therapeutics is focusing its core capabilities on developing new small molecule drugs to meet the unmet medical needs, and aims to develop new medicine for systemic lupus erythematosus, psoriasis, rheumatoid arthritis, Alzheimer's disease, nonalcoholic steatohepatitis, multiple sclerosis, and diabetes.

Platform Technology

Artificial Intelligence for
Development of New Drugs

Solid Basic Research
& Development

TLR Target New Drug
Discovery-POC Study, MOA Study

Global License Out

Open Innovation
& Technology IP Transfer